PMID- 31677945
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 81
IP  - 4
DP  - 2020 Apr
TI  - Soluble HLA-G pre-transplant levels to identify the risk for development of 
      infection in heart transplant recipients.
PG  - 147-150
LID - S0198-8859(19)31009-2 [pii]
LID - 10.1016/j.humimm.2019.10.003 [doi]
AB  - Infection is still a leading cause of death during the first year after heart 
      transplantation. We evaluated the pre-transplant levels of HLA (Human Leukocyte 
      antigen) - G molecules as a means of identifying heart recipients at risk of 
      serious infections. We prospectively analyzed 122 adult heart transplant (HT) 
      recipients. Serum samples were collected beforetransplantation and analyzed for 
      sHLA-G levels by ELISA assay. The clinical follow-up period lasted 5 years. 
      Clinical outcomes were bacterial infections requiring intravenous anti-microbial 
      agents, cytomegalovirus (CMV) disease, and fungal infections requiring therapy. 
      We found that 39 patients (32%) developed at least 1 serious bacterial infection. 
      Higher pre-transplant sHLA-G levels were a risk factor for serious infection 
      (above median value 5.4 ng/ml; relative risk 3.70; 95% confidence interval 
      1.03-12.64; p = 0.043). Patients with high levels of pre-transplant sHLA-G are 
      also characterized by a lower overall survival at 5 years (p = 0.017), with 
      microbial infections as major causes of death. No association was observed with 
      the development rejection episode. Early monitoring of sHLA-G molecules proved 
      useful for the identification of heart recipients who are at risk of serious 
      infections.
CI  - Copyright (c) 2019 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Bortolotti, Daria
AU  - Bortolotti D
AD  - Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 
      Ferrara, Italy.
FAU - Gentili, Valentina
AU  - Gentili V
AD  - Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 
      Ferrara, Italy.
FAU - Rotola, Antonella
AU  - Rotola A
AD  - Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 
      Ferrara, Italy.
FAU - Potena, Luciano
AU  - Potena L
AD  - Cardiovascular Department, University of Bologna, Bologna, Italy.
FAU - Rizzo, Roberta
AU  - Rizzo R
AD  - Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 
      Ferrara, Italy. Electronic address: rbr@unife.it.
LA  - eng
PT  - Journal Article
DEP - 20191031
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Biomarkers)
RN  - 0 (HLA-G Antigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Rejection/epidemiology
MH  - HLA-G Antigens/*blood
MH  - Heart Transplantation/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Opportunistic Infections/*blood/epidemiology/microbiology/virology
MH  - Preoperative Period
MH  - Risk
MH  - Survival Analysis
MH  - Young Adult
OTO - NOTNLM
OT  - HLA-G
OT  - Heart transplantation
OT  - Infection
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2019/11/05 06:00
MHDA- 2020/12/15 06:00
CRDT- 2019/11/04 06:00
PHST- 2019/07/18 00:00 [received]
PHST- 2019/10/08 00:00 [revised]
PHST- 2019/10/16 00:00 [accepted]
PHST- 2019/11/05 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2019/11/04 06:00 [entrez]
AID - S0198-8859(19)31009-2 [pii]
AID - 10.1016/j.humimm.2019.10.003 [doi]
PST - ppublish
SO  - Hum Immunol. 2020 Apr;81(4):147-150. doi: 10.1016/j.humimm.2019.10.003. Epub 2019 
      Oct 31.